難治性高血壓課件_第1頁(yè)
難治性高血壓課件_第2頁(yè)
難治性高血壓課件_第3頁(yè)
難治性高血壓課件_第4頁(yè)
難治性高血壓課件_第5頁(yè)
已閱讀5頁(yè)，還剩18頁(yè)未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明：本文檔由用戶(hù)提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

ResistantHypertension:Diagnosis,Evaluation,andTreatmentJENNY(AScientificStatementFromtheAmericanHeartAssociationProfessionalEducationCommitteeoftheCouncilforHighBloodPressureResearch)Objective

Expandingourunderstandingofthecausesofresistanthypertensionandtherebypotentiallyallowingformoreeffectivepreventionand/ortreatmentwillbeessentialtoimprovethelong-termclinicalmanagementofthisdisorder.1Contents23DiagnosisEvaluationTreatmentDefinition

bloodpressureremainsabovegoalthreeanti-hypertensiveagentsofdifferentclassesoneofthe3agentsshouldbeadiureticallagentsshouldbeprescribedatoptimaldoseamounts.ResistanthypertensionPrevalence1NHANES53%FraminghamHeartStudy48%ALLHAT250%PatientCharacteristicsPatientCharacteristicsAssociatedWithResistantHypertensionOlderageHighbaselinebloodpressureObesityExcessivedietarysaltingestionChronickidneydiseaseDiabetesLeftventricularhypertrophyBlackraceFemalesexResidenceinsoutheasternUnitedStatesPseudoresistancePoorBloodPressureTechniquePoorAdherenceLifestyleFactorsWhite-CoatEffectSecondaryCausesmeasuringthebloodpressurebeforelettingthepatientsitquietlyuseoftoosmallacuffPoorBloodPressureTechniqueamajorcauseoflackofbloodpressurecontrolPoorAdherencelessthan40%ofpatients40%ofpatientsthefirstyearoftreatment45to10yearsoffollow-up3White-CoatEffectStudiesindicatethatasignificantwhite-coateffect(whenclinicbloodpressuresarepersistentlyelevatedwhileout-of-officevaluesarenormalorsignificantlylower)isascommoninpatientswithresistanthypertensionasinthemoregeneralhypertensivepopulation,withaprevalenceintherangeof20%to30%.5LifestyleFactorsObesityisacommonfeatureofpatientswithresistanthypertension.ExcessivedietarysodiumintakeHeavyalcoholintakeisassociatedwithbothanincreasedriskofhypertension,aswellastreatment-resistanthypertension.Non-narcoticanalgesicsNon-steroidalanti-inflammatoryagents,includingaspirin,selectiveCOX-2inhibitors

Sympathomimeticagents(decongestants,dietpills,cocaine)Stimulants(methylphenidate,dexmethylphenidate,

dextroamphetamine,amphetamine,methamphetamine,

modafinil)AlcoholOralcontraceptivesCyclosporineEPONaturallicoriceHerbalcompounds(ephedraormahuang)Drug-RelatedCausesRenalartery

stenosisPrimaryaldosteronismRenalparenchymal

diseaseHyperparathyroidismCushing’sdiseasePheochromocytomaSecondaryCausesObstructiveSleepApneaAorticcoarctationEvaluationMedicalHistory:

duration,severity,progressionofthehypertension;treatmentadherence;responsetopriormedicationsAssessmentofAdherenceBloodPressureMeasurementsitquietlycorrectcuffsize;supportthearmatheartleveltheaverageof2readingssupineanduprightbloodpressuresPhysicalExaminationAmeanambulatorydaytimebloodpressureof<135/85mmHgisconsideredelevated.EvaluationAmbulatoryBloodPressureMonitoringBiochemicalEvaluationAroutinemetabolicprofileUrinalysisApaired,morningplasmaaldosterone

PlasmareninactivityNoninvasiveImagingTreatmentMaximizeAdherence

theuseofalong-actingcombinationofproducts

2.NonpharmacologicalRecommendationsWeightLossDietarySaltRestriction

ModerationofAlcoholIntakeIncreasedPhysicalActivityIngestionofaHigh-Fiber,Low-FatDiet3.TreatmentofSecondaryCausesofHypertension4.PharmacologicalTreatmentAliskirenEffectsofaliskirenandvalsartanonplasmaANGIandIIlevels.Aliskirenaloneorincombinationwithvalsartanwastestedin120mildlysodiumdepleted,Nor-motensiveadults(age,18to35years)inadouble-dummy,doubleblind,randomized,placebo-controlled,4-periodcrossoverstudy.Subjectsreceivedsingledosesofaliskiren300mgalone,aliskiren150mgincombinationwithvalsartan80mg,valsartan160mgalone,andplaceboseparatedby2-weekwashoutperiods

Thereisnodoubtthataliskirenisaneffectiveantihypertensiveagentandthatateffectivedosesitiswelltolerated.Itappearstobesafe,butthisstatementismadewiththeobviousqualificationforanynoveldrugorclassthatrareorlong-termadverseeventsmaytaketimetobecomeapparent.7AliskirenDOSE:75mg-300mgqd

p.oDarusentan

Darusentanprovidesadditionalreductioninbloodpressureinpatientswhohavenotattainedtheirtreatmentgoalswiththreeormoreantihypertensivedrugs.Aswithothervasodilatordrugs,fluidmanagementwitheffectivediuretictherapymightbeneeded.aVaccineAgainstHypertensionTargetingAngiotensinII,ReducesEarly-MorningandDay-TimeBloodPressureCYT006-AngQb

avirus-like-particlebasedconjugatevaccinetargeting(AngII)72mild-to-moderatehypertensivepatients.thevaccinewithanoptimizeddoseregimeninjectionsofeither100or300μg

CYT006-AngQbreducedbloodpressureinsituationswheretherenin-angiotensin-aldosteronesystem

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論